Abstract
More than 90% of cancer deaths are caused by cancer metastasis. Since cancer metastasis is the main cause of human deaths, so in this article more attention will be paid to it than ever before. Presently, clinical cancer chemotherapies have been targeting on primary tumors rather than on metastatic processes. Since the antimetastatic drugs are different from antiproliferative drugs and underinvestigated, cancer patients’ survival has been improved on a small scale now. To change this stalemate, this problem is reiterated by an analysis of the relationship between pathology, pharmacology and clinical therapy of neoplasm metastasis and it is suggested to improve the outcome of chemotherapy of cancer patients from different possible ways; e.g. to make more efforts to manufacture new types of antimetastatic drugs and optimize use of these drugs in clinics.
Keywords: Cancer chemotherapy, cancer medicinal chemistry, cancer treatment, cancer pathology, cancer pharmacology, neoplasm metastases.
Current Drug Therapy
Title:Cancer Metastasis Treatments
Volume: 8 Issue: 1
Author(s): Da-Yong Lu, Ting-Ren Lu, Hong-Ying Wu and Shan Cao
Affiliation:
Keywords: Cancer chemotherapy, cancer medicinal chemistry, cancer treatment, cancer pathology, cancer pharmacology, neoplasm metastases.
Abstract: More than 90% of cancer deaths are caused by cancer metastasis. Since cancer metastasis is the main cause of human deaths, so in this article more attention will be paid to it than ever before. Presently, clinical cancer chemotherapies have been targeting on primary tumors rather than on metastatic processes. Since the antimetastatic drugs are different from antiproliferative drugs and underinvestigated, cancer patients’ survival has been improved on a small scale now. To change this stalemate, this problem is reiterated by an analysis of the relationship between pathology, pharmacology and clinical therapy of neoplasm metastasis and it is suggested to improve the outcome of chemotherapy of cancer patients from different possible ways; e.g. to make more efforts to manufacture new types of antimetastatic drugs and optimize use of these drugs in clinics.
Export Options
About this article
Cite this article as:
Lu Da-Yong, Lu Ting-Ren, Wu Hong-Ying and Cao Shan, Cancer Metastasis Treatments, Current Drug Therapy 2013; 8(1) . https://dx.doi.org/10.2174/1574885511308010003
DOI https://dx.doi.org/10.2174/1574885511308010003 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
A Review of Recent Patents on the ASICs as a Key Drug Target
Recent Patents on Biotechnology Editorial Review 2015
Current Radiopharmaceuticals T-Lymphocytes: A Target for Stimulatory and Inhibitory Effects of Zinc Ions
Endocrine, Metabolic & Immune Disorders - Drug Targets Protective and Therapeutic Effects of Ghrelin in the Gut
Current Medicinal Chemistry The Quest for Surrogate Markers of Angiogenesis: A Paradigm for Translational Research in Tumor Angiogenesis and Anti- Angiogenesis Trials
Current Molecular Medicine Transdermal Drug Delivery: A Step towards Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery The Sphingolipid Rheostat: A Potential Target for Improving Pancreatic Islet Survival and Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Illuminating microRNA Transcription from the Epigenome
Current Genomics Short Commentary on “Targeting Long Non-Coding RNAs in Nervous System Cancers: New Insights in Prognosis, Diagnosis, and Therapy”
Current Medicinal Chemistry Patent Selections
Recent Patents on Biomarkers Clinical Vignettes: Integrated Care of Cancer Patients by Oncologists and Cardiologists
Current Cardiology Reviews Noradrenergic Regulation of Glial Activation: Molecular Mechanisms and Therapeutic Implications
Current Neuropharmacology Cot/Tpl-2 Protein Kinase as a Target for the Treatment of Inflammatory Disease
Current Topics in Medicinal Chemistry Saccharomyces Cerevisiae as a Genetic Model in Anticancer Therapy
Current Pharmacogenomics The Safety of Bisphosphonate Use in Premenopausal Women on Corticosteroids
Current Drug Safety Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials
Current Drug Targets Antidepressants: Update on Benefits and Risks
Current Psychopharmacology Radix Stephaniae Tetrandrine: An Emerging Role for Management of Breast Cancer
Current Pharmaceutical Design Untapped Potential of Disordered Proteins in Current Druggable Human Proteome
Current Drug Targets GSK-3 Inhibitors in the Regulation and Control of Colon Carcinoma
Current Drug Targets